Rituximab for Lymphoma

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Lymphoma+2 More
Rituximab - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing if it's safe to give rituximab, a cancer drug, into the spinal canal along with other chemo drugs.

Eligible Conditions
  • Lymphoma
  • Non-Hodgkin's Lymphoma (NHL)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Lymphoma

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: 28 months

28 months
Ability to deliver greater than 80% of planned doses
Related Grade 3 or higher non-hematological toxicity

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Lymphoma

Side Effects for

Rituximab
8%Mild/moderate allergic reactions
3%Severe allergic reaction
This histogram enumerates side effects from a completed 2016 Phase 2 & 3 trial (NCT03002038) in the Rituximab ARM group. Side effects include: Mild/moderate allergic reactions with 8%, Severe allergic reaction with 3%.

Trial Design

1 Treatment Group

Intrathecal rituximab
1 of 1
Experimental Treatment

20 Total Participants · 1 Treatment Group

Primary Treatment: Rituximab · No Placebo Group · Phase 2

Intrathecal rituximab
Drug
Experimental Group · 1 Intervention: Rituximab · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rituximab
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 28 months

Who is running the clinical trial?

Tahir LatifLead Sponsor
Tahir Latif, MDPrincipal Investigator - University of Cincinnati
University of Cincinnati Physicians, Inc.
Allama Iqbal Medical College (Medical School)
Cleveland Clinic Fndn (Residency)

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 8th, 2021

Last Reviewed: October 20th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.